p53 Antibodies in the sera of patients with various types of cancer: A review

Cancer Research

Volumn 60, Issue 7, 2000, Pages 1777-1788

  Soussi, Thierry ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; DNA; PROTEIN P53;

ANTIBODY SPECIFICITY; BREAST CANCER; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; COLON CANCER; EARLY DIAGNOSIS; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; MISSENSE MUTATION; MOUTH CANCER; NONHUMAN; OCCUPATIONAL EXPOSURE; ONCOGENE; PRIORITY JOURNAL; REVIEW; SERUM; SMOKING; STOMACH CANCER; TUMOR SUPPRESSOR GENE;

AUTOANTIBODIES; GENES, P53; HUMANS; MUTATION, MISSENSE; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034113998     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Melero, J. A., Stitt, D. T., Mangel, W. F., and Carroll, R. B. Identification of new polypeptide species (48-55K) imnmnoprecipitable by antiserum to purified large T antigen and present in simian virus 40-infected and transformed cells. J. Virol., 93: 466-480, 1979.
2. Linzer, D. I. H., and Levine., A. J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell, 17: 43-52, 1979.
3. Linzer, D. I., Maltzman, W., and Levine, A. J. The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology, 98: 308-318, 1979.
4. Lane, D. P., and Crawford, L. V. T antigen is bound to a host protein in SV40-transformed tells. Nature (Lond.), 278: 261-263, 1979.
5. Kress, M., May, E., Cassingena, R., and May, P. Simian Virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 serum. J. Virol., 31: 472-483, 1979.
6. Rotter, V., Witte, O. N., Coffman, R., and Baltimore, D. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein. p50. J. Virol., 36: 547-555, 1980.
7. De Leo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., and Old, L. J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA, 76: 2420-2424, 1979.
8. Crawford, L. V., Pim, D. C., and Bulbrook, R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer, 30: 403-408, 1982.
9. Caron de Fromentel, C., May-Levin, F., Mouriesse, H., Lemerle, J., Chandrasekaran, K., and May, P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39: 185-189, 1987.
10. Caron de Fromentel, C., and Soussi, T. TP53 tumor suppressor gene: a model for investigating human mutugenesis. Genes Chromosomes Cancer, 4: 1-15, 1992.
11. Crawford, L. The 53,000-dalton cellular protein and its role in transformation. Int. Rev. Exp. Pathol., 25: 1-50, 1983.
12. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
13. Oren, M., and Rotter, V. Introduction: p53 - the first twenty years. Cell. Mol. Life Sci., 55: 9-11, 1999.
14. Giaccia, A. J., and Kastan, M. B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev., 12: 2973-2983, 1998.
15. Prives, C. Signaling to p53: breaking the MDM2-p53 circuit. Cell, 95: 5-8, 1998.
16. Benchimol, S., Pim, D., and Crawford, L. Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J., 1: 1055-1062, 1982.
17. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
18. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
19. Soussi, T., Legros, Y., Lubin, R., Ory, K., and Schlichtholz, B. Multifactorial analysis of p53 alteration in human cancer - a review. Int. J. Cancer, 57: 1-9, 1994.
20. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
21. Béroud, C., and Soussi, T. p53 gene mutation: software and database. Nucleic Acids Res., 26: 200-204, 1998.
22. Casey, G., Lopez, M. E., Ramos, J. C., Plummer, S. J., Arboleda, M. J., Shaughnessy, M., Karlan, B., and Slamon, D. J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene, 13: 1971-1981, 1996.
23. Dowell, S. P., Wilson, P. O. G., Derias, N. W., Lane, D. P., and Hall, P. A. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res., 54: 2914-2918, 1994.
24. Angelopoulou, K., Diamandis, E. P., Sutherland, D. J. A., Kellen, J. A., and Bunting, P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer. 58: 480-487, 1994.
25. Lubin, R., Schlichtholz, B., Teillaud, J. L., Garay, E., Bussel, A., Wild, C., and Soussi, T. p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clin. Cancer Res., 1: 1463-1469, 1995.
26. Vennegoor, C., Nijman, H. W., Drijfhout, J. W., Vernie, L., Verstraeten, R. A., vonMensdorffPouilly, S., Hilgers, J., Verheijen, R. H. M., Kast, W. M., Melief, C. J. M., and Kenemans, P. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett., 116: 93-101, 1997.
27. Tavassoli, M., Brunel, N., Maher, R., Johnson, N. W., and Soussi, T. p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. Int. J. Cancer, 78: 390-391, 1998.
28. Angelopoulou, K., and Diamandis, E. P. Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. Eur. J. Cancer, 33: 115-121, 1997.
29. Munker, R., Stotzer, O., Darsow, M., Classen, S., Lebeau, A., and Wilmanns, W. Autoantibodies against p53 are not increased in human ascites and pleural effusions. Cancer Immunol. Immunother., 42: 200-201, 1996.
30. Puisieux, A., Galvin, K., Troalen, F., Bressac, B., Marcais, C., Galun, E., Ponchel, F., Yakicier, C., Ji, J. W., and Ozturk, M. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J., 7: 1407-1413, 1993.
31. Fleischhacker, M., Strohmeyer, T., Imai, Y., Slamon, D. J., and Koeffler, H. P. Mutations of the p53 gene are not detectable in human testicular tumors. Mod. Pathol., 7: 435-439, 1994.
32. Peng, H. Q., Hogg, D., Malkin, D., Bailey, D., Gallie, B. L., Bulbul, M., Jewett, M., Buchanan, J., and Goss, P. E. Mutations of the p53 gene do not occur in testis cancer. Cancer Res., 53: 3574-3578, 1993.
33. Lubbe, J., Reichel, M., Burg, G., and Kleihues, P. Absence of p53 gene mutations in cutaneous melanoma. J. Investig. Dermatol., 102: 819-821, 1994.
34. Luca, M., Lenzi, R., Lee-Jackson, D., Gutman, M., Fidler, I. J., and Bar-Eli, M. p53 mutations are infrequent and do not correlate with the metastatic potential of human melanoma cells. Int. J. Oncol., 3: 19-22., 1993.
35. Rainov, N. G., Dobberstein, K. U., Fittkau, M., Bahn, H., Holzausen, H. J., Gantchev, L., and Burkert, W. Absence of p53 antibodies in sera from glioma patients. Clin. Cancer Res., 1: 775-781, 1995.
36. Weller, M., Bornemann, A., Stander, M., Schabet, M., Dichgans, J., and Meyermann, R. Humoral immune response to p53 in malignant glioma. J. Neurol., 245: 169-172, 1998.
37. Ohgaki, H., Eibl, R. H., Schwab, M., Reichel, M. B., Mariani, L., Gehring, M., Petersen, I., Holl, T., Wiestler, O. D., and Kleihues, P. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol. Carcinog., 8: 74-80, 1993.
38. Winter, S. F., Minna, J. D., Johnson, B. E., Takahashi, T., Gazdar, A. F., and Carbone, D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res., 52: 4168-4174, 1992.
39. Davidoff, A. M., Iglehart, J. D., and Marks, J. R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl. Acad. Sci. USA, 89: 3439-3442, 1992.
40. Kaur, J., Srivastava, A., and Ralhan, R. Serum p53 antibodies in patients with oral lesions: Correlation with p53/HSP70 complexes. Int. J. Cancer, 74: 609-613, 1997.
41. Winter, S. F., Sekido, Y., Minna, J. D., Mcintire, D., Johnson, B. E., Gazdar, A. F., and Carbone, D. P. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer - association with improved survival. J. Natl. Cancer Inst., 85: 2012-2018, 1993.
42. Trivers, G. E., Cawley, H. L., Debenedetti, V. M. G., Hollstein, M., Marion, M. J., Bennett, W. P., Hoover, M. L., Prives, C. C., Tamburro, C. C., and Harris, C. C. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J. Natl. Cancer Inst., 87: 1400-1407, 1995.
43. Hammel, P., LeroyViard, K., Chaumette, M. T., Villaudy, J., Falzone, M. C., Rouillard, D., Hamelin, R., Boissier, B., and Remvikos, Y. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int. J. Cancer, 81: 712-718, 1999.
44. von Brevern, M. C., Hollstein, M. C., Cawley, H. M., De Benedetti, V. M. G., Bennett, W. P., Liang, L., He, A. G., Zhu, S. M., Tursz, T., Janin, N., and Trivers, G. E. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res., 56: 4917-4921, 1996.
45. Schlichtholz, B., Legros, Y., Gillet, D., Gaillard, C., Marty, M., Lane, D., Calvo, F., and Soussi, T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res., 52: 6380-6384, 1992.
46. Labrecque, S., Naor, N., Thomson, D., and Matlashewski, G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res., 53: 3468-3471, 1993.
47. Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Tredaniel, J., Hirsch, A., Caron de Fromentel, C., Preudhomme, C., Fenaux, P., Fournier, G., Mangin, P., Laurent-Puig, P., Pelletier, G., Schlumberger, M., Desgrandchamps, F., Leduc, A., Peyrat, J. P., Janin, N., Bressac, B., and Soussi, T. Analysis of p53 antibodies in patients with various cancers define B-Cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res., 53: 5872-5876, 1993.
48. Schlichtholz, B., Tredaniel, J., Lubin, R., Zalcman, G., Hirsch, A., and Soussi, T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer, 69: 809-816, 1994.
49. Legros, Y., Lafon, C., and Soussi, T. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino- and carboxy-termini of the protein. Oncogene, 9: 2071-2076, 1994.
50. Hardy-Bessard, A. C., Garay, E., Lacronique, V., Legros, Y., Demarquay, C., Houque, A., Portefaix, J. M., Granier, C., and Soussi, T. Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein. Oncogene, 16: 883-890, 1998.
51. Vojtesek, B., Bartek, J., Midgley, C. A., and Lane, D. P. An immunochemical analysis of the human nuclear phosphoprotein-p53: new monoclonal antibodies and epitope mapping using recombinant-p53. J. Immunol. Methods. 151: 237-244, 1992.
52. Bartek, J., Bartkova, J., Lukas, J., Staskova, Z., Vojtesek, B., and Lane, D. P. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J. Pathol., 169: 27-34, 1993.
53. Legros, Y., Meyer, A., Ory, K., and Soussi, T. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene, 9: 3689-3694, 1994.
54. Vojtesek, B., Dolezalova, H., Lauerova, L., Svitakova, M., Havlis, P., Kovarik, J., Midgley, C. A., and Lane, D. P. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene, 10: 389-393, 1995.
55. Levesque, M. A., Dcosta, M., and Diamandis, E. P. p53 protein is absent from the serum of patients with lung cancer. Br. J. Cancer, 74: 1434-1440, 1996.
56. Hassapoglidou, S., Diamandis, E. P., and Sutherland, D. J. A. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene, 8: 1501-1509, 1993.
57. Cho, Y. J., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. Crystal structure of a p53 tumor suppressor DNA complex: understanding tumorigenic mutations. Science (Washington DC), 265: 346-355, 1994.
58. Portefaix, J. M., Thébault, S., Bourgain-Guglielmetti, F., Del Rio, M., Granier, M., Mani, J. C., Teulon-Navaro, I., Nicolas, M., Soussi, T., and Pau, B. Critical residues of epitopes recognized by several anti-p53 monoclonal antibodies correspond to key residues of p53 involved in interaction with the mdm2 protein. J. Immunol. Methods, in press, 2000.
59. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90: 809-819, 1997.
60. Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., and Ikawa, S. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med., 4: 839-843, 1998.
61. Trink, B., Okami, K., Wu, L., Sriuranpong, V., Jen, J., and Sidransky, D. A new human p53 homologue. Nat. Med., 4: 747-748, 1998.
62. Schmale, H., and Bamberger, C. A novel protein with strong homology to the tumor suppressor p53. Oncogene, 25: 1363-1367, 1997.
63. Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E., and Levine, A. J. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc. Natl. Acad. Sci. USA, 93: 4781-4786, 1996.
64. Peyrat, J. P., Bonneterre, J., Lubin, R., Vanlemmens, L., Fournier, J., and Soussi, T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet, 345: 621-622, 1995.
65. Mudenda, B., Green, J. A., Green, B., Jenkins, J. R., Robertson, L., Tarunina, M., and Leinster, S. J. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br. J. Cancer, 69: 1115-1119, 1994.
66. Lenner, P., Wiklund, F., Emdin, S. O., Arnerlov, C., Eklund, C., Hallmans, G., Zentgraf, H., and Dillner, J. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br. J. Cancer, 79: 927-932, 1999.
67. Willsher, P. C., Pinder, S. E., Robertson, L., Nicholson, R. I., Ellis, I. O., Bell, J. A., Blarney, R. W., Green, J. A., and Robertson, J. F. R. The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res., 16: 927-930, 1996.
68. Porzolt, F., M., S., Hoher, D., Muche, D., Gaus, W., and Montenarh, M. Biological relevance of auto-antibodies against p53 in patients with metastatic breast cancer. Onkologie., 17: 402-408, 1994.
69. Maehara, Y., Kakeji, Y., Watanabe, A., Baba, H., Kusumoto, H., Kohnoe, S., and Sugimachi, K. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer (Phila.), 85: 302-308, 1999.
70. Wu, C. W., Lin, Y. Y., Chen, G. D., Chi, C. W., Carbone, D. P., and Chen, J. Y. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br. J. Cancer, 80: 483-488, 1999.
71. Shiota, G., Ishida, M., Noguchi, N., Takano, Y., Oyama, K., Okubo, M., Katayama, S., Harada, K., Hori, K., Ashida, K., Kishimoto, Y., Hosoda, A., Suou, T., Ito, H., and Kawasaki, H. Clinical significance of serum p53 antibody in patients with gastric cancer. Res. Commun. Mol. Pathol. Pharmacol., 99: 41-51, 1998.
72. Kressner, U., Glimelius, B., Bergstrom, R., Pahlman, L., Larsson, A., and Lindmark, G. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br. J. Cancer, 77: 1848-1851, 1998.
73. Houbiers, J. G. A., Vanderburg, S. H., Vandewatering, L. M. G., Tollenaar, R. A. E. M., Brand, A., Vandevelde, C. J. H., and Melief, C. J. M. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br. J. Cancer, 72: 637-641, 1995.
74. Angelopoulou, K., Stratis, M., and Diamandis, E. P. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int. J. Cancer, 70: 46-51, 1997.
75. Laudanski, J., Burzykowski, T., Niklinska, W., Chyczewski, K., Furman, M., and Niklinski, J. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. Lung Cancer, 22: 191-200, 1998.
76. Lai, C-L., Tsai, C-M., Tsai, T-T., Ing-Tiau Kuo, B., Chang, K-T., Fu, H-T., Perng, R-P., and Chen, J-Y. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin. Cancer Res., 4: 3025-3030, 1998.
77. Komiya, T., Hirashima, T., Takada, M., Masuda, N., Yasumitsu, T., Nakagawa, K., Hosono, Y., Kikui, M., Tsuji, S., Fukuoka, M., and Kawase, I. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res., 17: 3721-3724, 1997.
78. Zalcman, G., Trédaniel, G., Schlichtholz, B., Urban, T., Milleron, B., Lubin, R., Meignin, V., Couderc, J. L., Hirsch, A., and Soussi, T. Prognostic significance of serum p53 antibody in patients with limited-stage small cell lung cancer. Int. J. Cancer, 89: 81-86, 2000.
79. Rosenfeld, M. R., Malats, N., Schramm, L., Graus, F., Cardenal, F., Vinolas, N., Rosell, R., Tora, M., Real, F. X., Posner, J. B., and Dalmau, J. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J. Natl. Cancer Inst., 89: 381-385, 1997.
80. Bourhis, J., Lubin, R., Roche, B., Koscielny, S., Bosq, J., Dubois, I., Talbot, M., Marandas, P., Schwaab, G., Wibault, P., Luboinski, B., Eschwege, F., and Soussi, T. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J. Natl. Cancer Inst., 88: 1228-1233, 1996.
81. Werner, J. A., Gottschlich, S., Folz, B. J., Goeroegh, T., Lippert, B. M., Maass, J. D., and Rudert, H. p53 serum antibodies as prognostic indicator in head and neck cancer. Cancer Immunol. Immunother., 44: 112-116, 1997.
82. Hammel, P., Boissier, B., Chaumette, M. T., Piedbois, P., Rotman, N., Kouyoumdjian, J. C., Lubin, R., Delchier, J. C., and Soussi, T. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut, 40: 356-361, 1997.
83. Zalcman, G., Schlichtholz, B., Trédaniel, J., Urban, T., Lubin, R., Dubois, I., Milleron, B., Hirsh, A., and Soussi, T. Monitoring of p53 auto antibodies in lung cancer during therapy: relationship to response to treatment. Clin. Cancer Res., 4: 1359-1366, 1998.
84. Saffroy, R., Lelong, J. C., Azoulay, D., Salvucci, M., Reynes, M., Bismuth, H., Debuire, B., and Lemoine, A. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. Br. J. Cancer, 79: 604-610, 1999.
85. Polge, A., Bourgaux, J. F., Bancel, E., Pignodel, C., Boyer, J. C., Poirey, S., DeBornier, B. M., Balmes, J. L., and Bali, J. P. p53 and follow-up of colorectal adenocarcinomas. Dig. Dis. Sci., 43: 1434-1442, 1998.
86. Gadducci, A., Ferdeghini, M., Buttitta, F., Cosio, S., Fanucchi, A., Annicchiarico, C., and Genazzani, A. R. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. Anticancer Res., 18: 3763-3766, 1998.
87. Shimada, H., Arima, M., Nakajima, K., Koide, Y., Okazumi, S., Matsubara, H., Miyazawa, Y., Takeda, A., Hayashi, H., Yoshida, T., Ochiai, T., and Isono, K. "Detection of serum p53 antibodies in mucosal esophageal cancer and negative conversion after treatment" (Letter). Am. J. Gastroenterol., 93: 1388-1389, 1998.
88. Lubin, R., Zalcman, G., Bouchet, L., Trédaniel, J., Legros, Y., Cazals, D., Hirsh, A., and Soussi, T. Serum p53 antibodies as early markers of lung cancer. Nat Med., 1: 701-702, 1995.
89. Bennett, W. P., Colby, T. V., Travis, W. D., Borkowski, A., Jones, R. T., Lane, D. P., Metcalf, R. A., Samet, J. M., Takeshima, Y., Gu, J. R., Vahakangas, K. H., Soini, Y., Paakko, P., Welsh, J. A., Trump, B. F., and Harris, C. C. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res., 53: 4817-4822, 1993.
90. Trivers, G. E., De Benedetti, V. M. G., Cawley, H. L., Caron, G., Harrington, A. M., Bennet, W. P., Jett, J. R., Colby, T. V., Tazelaar, H., Pairolero, P., Miller, R. D., and Harris, C. C. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin. Cancer Res., 2: 1767-1775, 1996.
91. Cawley, H. M., Meltzer, S. J., De Benedetti, V. M., Hollstein, M. C., Muehlbauer, K. R., Liang, L., Bennett, W. P., Souza, R. F., Greenwald, B. D., Cottrell, J., Salabes, A., Bartsch, H., and Trivers, G. E. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology, 115: 19-27, 1998.
92. Ralhan, R., Nath, N., Agarwal, S., Mathur, M., Wasylyk, B., and Shukla, N. K. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin. Cancer Res., 4: 2147-2152, 1998.
93. Parashar, K., and Sobti, R. C. A study on p53 protein and anti-p53 antibodies in the sera of patients with oesophageal cancer. Mutat. Res. Fundam. Mol. Mech. Mutat., 422: 271-277, 1998.
94. Partanen, R., Koskinen, H., Oksa, P., Hemminki, K., Carney, W., Smith, S., and Brandtrauf, P. Serum oncoproteins in asbestosis patients. Clin. Chem., 41: 1844-1847, 1995.
95. Luo, J. C., Zehah, R., Anttila, S., Ridanpaa, M., Husgafvel-Pursiainen, K., Vainio, H., Carney, W., DeVivo, I., Milling, C., and Brandt-Rauf, P. W. Detection of serum p53 protein in lung cancer patients. J. Occup. Med., 36: 155-160, 1994.
96. Luo, J. C. Neugol, A. I., Garbowski, G., Forde, K. A., Treat, M., Smith, S., Carney, W. P., and Brandt-Rauf, P. W. Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett., 8: 235-240, 1995.
97. Wong, S. K., SeowChoen, F., Leong, A. P. K., Ho, Y. H., and Aw, S. E. Mutant plasma p53 protein levels: prognostication in colorectal carcinoma. Br. J. Surg., 84: 664-665, 1997.
98. Zusman, I., Zusman, R., Sandler, B., Korol, D., Gurevich, P., Smirnoff, P., Bass, D., Or, A., Shani, A., Idelevich, E., Huszar, M., Tendler, Y., Klein, T., Shezen, E., and Glick, J. HPLC determination of serum levels of soluble p53 antigen as a new method for colon cancer detection, and its clinical implication: clinical study. Int. J. Oncol., 8: 1249-1256, 1996.
99. Takahashi, M., Chen, W., Byrd, D. R., Disis, M. L., Huseby, E. S., Qin, H., McCahill, L., Nelson, H., Shimada, H., Okuno, K., Yasutomi, M., Peace, D. J., and Cheever, M. A. Antibody to ras proteins in patients with colon cancer. Clin. Cancer Res., 1: 1071-1077, 1995.
100. Sorokine, I., Ben-Mahrez, K., Bracone, A., Thierry, D., Ishii, S., Imamoto, F., and Kohiyama, M. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int. J. Cancer, 47: 665-669, 1991.
101. Yamamoto, A., Shimizu, E., Ogura, T., and Sone, S. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int. J. Cancer, 69: 283-289, 1996.
102. Ben-Mahrez, K., Thierry, D., Sorokine, I., Danna-Muller, A., and Kohiyama, M. Detection of circulating antibodies against c-myc protein in cancer patient sera. Br. J. Cancer, 57: 529-534, 1988.
103. Selter, H., Amela-Neuschwander, S., Villena-Heinsen, C., and Montenarh, M. Antibodies against murine double minute-2 (mdm2) in sera of patients with various gynaecological diseases. Cancer Lett., 96: 111-115, 1995.
104. Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., and Cheever, M. A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol., 15: 3363-3367, 1997.
105. Ward, R. L., Hawkins, N. J., Coomber, D., and Disis, M. L. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. Hum. Immunol., 60: 510-515, 1999.
106. Chen, Y. T., Scanlan, M. J., Sahin, U., Tureci, O., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L. J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA, 94: 1914-1918, 1997.
107. Tureci, O., Sahin, U., and Pfreundschuh, M. Serological analysis of human tumor antigens: molecular definition and implications. Mol. Med. Today, 3: 342-349, 1997.
108. Mao, L., Lee, J. S., Kurie, J. M., Fan, Y. H., Lippman, S. M., Lee, J. J., Ro, J. Y., Broxson, A., Yu, R.. Morice, R. C., Kemp, B. L., Khuri, F. R., Walsh, G. L., Hittelman, W. N., and Hong, W. K. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst., 89: 857-862, 1997.
109. Rusin, M., Butkiewicz, D., Malusecka, E., Zborek, A., Harasim, J., Czyzewski, K., Bennett, W. P., Shields, P. G., Weston, A., Welsh, J. A., Krzyzowska-Gruca, S., Chorazy, M., and Harris, C. C. Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland. Br. J. Cancer, 80: 1445-1452, 1999.
110. Volkmann, M., Muller, M., Hofmann, W. J., Meyer, M., Hagelstein, J., Rath. U., Kommerell, B., Zentgraf, H., and Galle, P. R. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status. Hepatology, 18: 559-565, 1993.
111. Green, J. A., Mudenda, B., Jenkins, J., Leinster, S. J., Tarunina, M., Green, B., and Robertson, L. Serum p53 auto-antibodies: incidence in familial breast cancer. Eur. J. Cancer, 30A: 580-584, 1994.
112. Wild, C. P., Ridanpaa, M., Anttila, S., Lubin, R., Soussi, T., Husgafvel-Fursiainen, K., and Vainino, H. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int. J. Cancer, 64: 176-181, 1995.
113. Mayerhofer, K., Tempfer, C., Kucera, E., Hefler, L., Zeisler, H., Kainz, C., Zeillinger, R., and Sliutz, G. Humoral p53 antibody response is a prognostic parameter in ovarian cancer. Anticancer Res., 19: 875-878, 1999.
114. Iizasa, T., Fujisawa, T., Saitoh, Y., Hiroshima, K., and Ohwada, H. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma. Cancer Immunol. Immunother., 46: 345-349, 1998.
115. Hallak, R., Mueller, J., Lotter, O., Gansauge, S., Gansauge, F., Jumma, M. E., Montenarh, M., Safi, F., and Beger. H. p53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: a comparative study. Int. J. Oncol., 12: 785-791, 1998.
116. Shiota, G., Kishimoto, Y., Suyama, A., Okubo, M., Katayama, S., Harada, K., Ishida, M., Hori, K., Suou, T., and Kawasaki, H. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. J. Hepatol., 27: 661-668, 1997.
117. Green, J. A., Roberston, L. J., Campbell, I. R., and Jenkins, J. expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect. Prev., 19: 151-155, 1995.
118. Raedle, J., Roth, W. K., Oremek, G., Caspary, W. F., and Zeuzem, S. α-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig. Dis. Sci., 40: 2587-2594, 1995.
119. Maass, J. D., Gottschlich, S., Lippert, B. M., Niemann, A. M., Goeroegh, T., and Werner, J. A. Antibodies in response to the cellular protein p53 in patients with squamous cell carcinoma of the head and neck. Laryngo- Rhino- Otol., 75: 53-56, 1996.
120. Coomber, D., Hawkins, N. J., Clark, M., Meagher, A., and Ward, R. L. Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J. Cancer Res. Clin. Oncol., 122: 757-762, 1996.
121. Shibata, Y., Kotanogi, H., Andoh, H., Koyama, K., Itoh, H., and Kudo, S. Detection of circulating anti p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Dis. Colon Rectum, 39: 1269-1274, 1996.
122. Ryder, S. D., Rizzi, P. M., Volkmann, M., Metivier, E., Pereira, L. M. M. B., Galle, P. R., Naoumov, N. V., Zentgraf, H., and Williams, R. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J. Clin. Pathol., 49: 295-299, 1996.
123. Gansauge, S., Gansauge, F., Negri, G., Galle, P., Muller, J., Nussler, A. K., Poch, B., and Beger, H. G. The role of anti-p53-autoantibodies in pancreatic disorders. Int. J. Pancreatol., 19: 171-178, 1996.
124. Sthoeger, Z., Evron, E., Goland, S., Shani, A., Wolkowicz, R., Goldfinger, N., Rotter, V., and Fogel, M. Anti-p53 antibodies in colon cancer patients. Ann. NY. Acad. Sci., 815: 496-498, 1997.
125. Friedrich, R. E., BartelFriedrich, S., Plambeck, K., Bahlo, M., and Klapdor, R. p53 auto-antibodies in the sera of patients with oral squamous cell carcinoma. Anticancer Res., 17: 3183-3184, 1997.
126. Wollenberg, B., Jan, N. V., Pitzke, P., Reiter, W., and Stieber, P. Anti-p53 antibodies in serum of smokers and head and neck cancer patients. Anticancer Res., 17: 413-418, 1997.
127. Crawford, L. V., Pim, D. C., and Lamb, P. The cellular protein p53 in human tumors. Mol. Biol. Med., 2: 261-272, 1984.
128. Angelopoulou, K., and Diamandis, E. P. Autoantibodies against the p53 tumor suppressor gene product quantified in cancer patients serum with time-resolved immunofluorometry. The Cancer J., 6: 315-321, 1993.
129. Regidor, P. A., Regidor, M., Callies, R., and Schindler, A. E. Detection of p53 auto-antibodies in the sera of breast cancer patients with new reccurence using an ELISA assay. Eur. J. Gynaecol. Oncol., 17: 192-199, 1996.
130. Guinee, D. G., Travis, W. D., Trivers, G. E., Debenedetti, V. M. G., Cawley, H., Welsh, J. A., Bennett, W. P., Jett, J., Colby, T. V., Tazelaar, H., Abbondanzo, S. L., Pairolero, P., Trastek, V., Caporaso, N. E., Liotta, L. A., and Harris, C. C. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis (Lond.), 16: 993-1002, 1995.
131. Bergqvist, M., Brattstrom, D., Larsson, A., Holmertz, J., Hesselius, P., Rosenberg, L., Wagenius, G., and Brodin, O. p53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Anticancer Res., 18: 1999-2002, 1998.
132. Mitsudomi, T., Suzuki, S., Yatabe, Y., Nishio, M., Kuwabara, M., Gotoh, K., Hatooka, S., Shinoda, M., Suyama, M., Ogawa, M., Takahashi, T., and Ariyoshi, Y. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J. Natl. Cancer Inst., 90: 1563-1568, 1998.
133. Royer, B., CazalsHatem, D., Sibilia, J., Agbalika, F., Cayuela, J. M., Soussi, T., Maloisel, F., Clauvel, J. P., Brauet, J. C., and Mariette, X. Lymphomas in patients with Sjögren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood, 90: 766-775, 1997.
134. Nakajima, K., Suzuki, T., Shimada, H., Hayashi, H., Takeda, A., and Ochiai, T. Detection of preoperative serum anti-p53 antibodies in gastric cancer. Tumor Biol., 20: 147-152, 1999.
135. Cough, M. J., Koch, M., Brennan, J. A., and Sidransky, D. The humoral response to oncoprotein p53 in head and neck cancer. Head Neck, 16: 495, 1994.
136. Lavieille, J. P., Righini, C., Reyt, E., Brambilla, C., and Riva, C. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas. Oral Oncol., 34: 84-92, 1998.
137. Maass, J. D., Gottschlich, S., Goeroegh, T., Lippert, B. M., and Werner, J. A. Head and neck cancer and p53-immunogenicity. Anticancer Res., 17: 2873-2874, 1997.
138. Maass, J. D., Gottschlich, S., Niemann, A. M., Goeroegh, T., Lippert, B. M., and Werner, J. A. Serum p53-antibodies in head and neck cancer. In: J. A. Werner, B. M. Lippert, and H. H. Lippert (eds.), Head and Neck Cancer: Advances in Basic Research, Vol. 1114, pp. 351-355. London: Elsevier, 1996.
139. Lavieille, J. P., Lubin, R., Soussi, T., Reyt, E., Brambilla, C., and Riva, C. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. Anticancer Res., 16: 2385-2388, 1996.
140. Collet, B., Raoul, J. L., LeBerre, N., Heresbach, D., Merilte, H., Quillien, V., and DeCertaines, J. D. Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus: comparison with p53 alterations and lymph node invasion. Int. J. Oncol., 11: 617-621, 1997.
141. Shimada, H., Nakajima, K., Ochiai, T., Koide, Y., Okazumi, S. I., Matsubara, H., Takeda, A., Miyazawa, Y., Arima, M., and Isono, K. Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers. Oncol. Rep., 5: 871-874, 1998.
142. Edis, C. Kahler, C., Klotz, W., Herold, M., Feichtinger, H., Konigsreiner, A., Margreiter, R., Jaschke, W., and Vogel, W. A comparison between α-fetoprotein and p53 antibodies in the diagnosis of hepatoccllular carcinoma. Transplant. Proc., 30: 780-781, 1998.
143. Gadducci, A., Ferdeghini, M., Buttitta, F., Cosio, S., Fanucchi, A., Annicchiarico, C., Gagetti, O., Bevilacqua, G., and Genazzani, A. R. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol. Oncol., 72: 76-81, 1999.
144. Gadducci, A., Ferdeghini, M., Buttitta, F., Fanucchi, A., Annicchiarico, C., Prontera, C., Bevilacqua, G., and Genazzani, A. R. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. Anticancer Res., 16: 3519-3523, 1996.
145. Angelopoulou, K., Rosen, B., Stratis, M., Yu, H., Solomou, M., and Diamandis, E. P. Circulating antibodies against p53 protein in patients with ovarian carcinoma: correlation with clinicopathologic features and survival. Cancer (Phila.), 78: 2146-2152, 1996.
146. Marxsen, J., Schmiegel, W., Roder, C., Harder, R., Juhl, H., Hennebruns, D., Kremer, B., and Kalthoff, H. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br. J. Cancer, 70: 1031-1034, 1994.
147. Laurent-Puig, P., Lubin, R., Semhounducloux, S., Pelletier, G., Fourre, C., Ducreux, M., Briantais, M. J., Buffet, C., and Soussi, T. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut, 36: 455-458, 1995.
148. Raedle, J., Oremek, G., Welker, M., Roth, W. K., Caspary, W. F., and Zeuzem, S. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas, 13: 241-246, 1996.
149. Chen, Y. M. A., Chen, S. H., Fu, C. Y., Chen, J. Y., and Osame, M. Antibody reactivities to tumor-suppressor protein p53 and HTLV-I Tof Rex and Tax in HTLV-I-infected people with differing clinical status. Int. J. Cancer, 71: 196-202, 1997.
150. Preudhomme, C., Vanrumbeke, M., Detourmignies, L., Facon, T., Lepelley, P., Soussi, T., and Fenaux, P. Very low incidence of p53 antibodies in adult non-Hodgkin's lymphoma and multiple myeloma. Br. J. Haematol., 100: 184-186, 1998.
151. Pulkki, K., Ollikainen, H., Rajamaki, A., and Pelliniemi, T. T. serum p53 oncoprotein and p53 antibodies as prognostic factor in multiple myeloma (MM). Blood, 86: 64a, 1995